Gideon Koren

Prof. Dr. Gideon Koren

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2013 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
SGSophie Grigoriadis
Sophie Grigoriadis
EVEmily H. VonderPorten
Emily H. VonderPorten
LMLana Mamisashvili
Lana Mamisashvili
GTGeorge A. Tomlinson
George A. Tomlinson
CDCindy-Lee Dennis
Cindy-Lee Dennis
LRLori E. Ross
Lori E. Ross
From The Journal of Clinical Psychiatry:

1 August 2006 in The Lancet
Verified
Journal Article
Closed access
GKGideon Koren
Gideon Koren
JCJames Cairns
James Cairns
DCDavid Chitayat
David Chitayat
AGAndrea Gaedigk
Andrea Gaedigk
SLSteven J Leeder
Steven J Leeder

3 November 2015 in Circulation
Verified
Journal Article
Closed access
FJFarida M. Jeejeebhoy
Farida M. Jeejeebhoy
CZCarolyn M. Zelop
Carolyn M. Zelop
SLSteve Lipman
Steve Lipman
BCBrendan Carvalho
Brendan Carvalho
JJJose Joglar
Jose Joglar
CCClifton W. Callaway
Clifton W. Callaway
This is the first scientific statement from the American Heart Association on maternal resuscitation. This document will provide readers with up-to-date and comprehensive information, guidelines, and recommendations for all aspects of maternal resuscitation. Maternal resuscitation is an acute event that involves many subspecialties and allied health providers; this document will be relevant to all healthcare providers who are involved in resuscitation and specifically maternal resuscitation.

26 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OBOlivia S. Beane
Olivia S. Beane
VFVera C. Fonseca
Vera C. Fonseca
LCLeroy L. Cooper
Leroy L. Cooper
GKGideon Koren
Gideon Koren
EDEric M. Darling
Eric M. Darling
Mesenchymal stem/stromal cells (MSCs) are promising cell sources for regenerative therapies due to their multipotency and ready availability, but their application can be complicated by patient-specific factors like age or illness. MSCs have been investigated for the treatment of many musculoskeletal disorders, including osteoarthritis and osteoporosis. Due to the prevalence of these diseases in older populations, researchers have studied how aging affects MSC properties and have found that proliferation and differentiation potential are impaired. However, these effects have never been compared among MSCs isolated from multiple tissue sources in the same, healthy donor. Revealing differences in how MSCs are affected by age could help identify an optimal cell source for musculoskeletal therapies targeting older patients. MSCs were isolated from young and old rabbit bone marrow, muscle, and adipose tissue. Cell yield and viability were quantified after isolation procedures, and expansion properties were assessed using assays for proliferation, senescence, and colony formation. Multipotency was also examined using lineage-specific stains and spectrophotometry of metabolites. Results were compared between age groups and among MSC sources. Results showed that MSCs are differentially influenced by aging, with bone marrow-derived stem cells having impaired proliferation, senescence, and chondrogenic response, whereas muscle-derived stem cells and adipose-derived stem cells exhibited no negative effects. While age reduced overall cell yield and adipogenic potential of all MSC populations, osteogenesis and clonogenicity remained unchanged. These findings indicate the importance of age as a factor when designing cell-based therapies for older patients.

20 August 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CCCatherine Ciszkowski
Catherine Ciszkowski
PMParvaz Madadi
Parvaz Madadi
MPMichael S. Phillips
Michael S. Phillips
ALAlbert E. Lauwers
Albert E. Lauwers
GKGideon Koren
Gideon Koren
Obstructive sleep apnea is not rare in children with hypertrophic tonsils, and the common curative procedure is adenotonsillectomy.1 Codeine is commonly prescribed for pain after adenotonsillectomy.2 The respiratory depressant effects of opioids may influence the occurrence of respiratory complications.3 An estimated one third of cases of apnea in children are not resolved after adenotonsillectomy.4

1 November 2016 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
GPGali Pariente
Gali Pariente
TLTom Leibson
Tom Leibson
ACAlexandra Carls
Alexandra Carls
TAThomasin Adams-Webber
Thomasin Adams-Webber
SIShinya Ito
Shinya Ito
GKGideon Koren
Gideon Koren
Women are commonly prescribed a variety of medications during pregnancy. As most organ systems are affected by the substantial anatomical and physiological changes that occur during pregnancy, it is expected that pharmacokinetics (PK) (absorption, distribution, metabolism, and excretion of drugs) would also be affected in ways that may necessitate changes in dosing schedules. The objective of this study was to systematically identify existing clinically relevant evidence on PK changes during pregnancy. Systematic searches were conducted in MEDLINE (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials (Ovid), and Web of Science (Thomson Reuters), from database inception to August 31, 2015. An update of the search from September 1, 2015, to May 20, 2016, was performed, and relevant data were added to the present review. No language or date restrictions were applied. All publications of clinical PK studies involving a group of pregnant women with a comparison to nonpregnant participants or nonpregnant population data were eligible to be included in this review. A total of 198 studies involving 121 different medications fulfilled the inclusion criteria. In these studies, commonly investigated drug classes included antiretrovirals (54 studies), antiepileptic drugs (27 studies), antibiotics (23 studies), antimalarial drugs (22 studies), and cardiovascular drugs (17 studies). Overall, pregnancy-associated changes in PK parameters were often observed as consistent findings among many studies, particularly enhanced drug elimination and decreased exposure to total drugs (bound and unbound to plasma proteins) at a given dose. However, associated alterations in clinical responses and outcomes, or lack thereof, remain largely unknown. This systematic review of pregnancy-associated PK changes identifies a significant gap between the accumulating knowledge of PK changes in pregnant women and our understanding of their clinical impact for both mother and fetus. It is essential for clinicians to be aware of these unique pregnancy-related changes in PK, and to critically examine their clinical implications.